PBM employs commercially available non-thermal device-based techniques that utilize light from LEDs or lasers in the red to near-infrared (NIR) spectrum. This light stimulates cellular processes, notably in mitochondria, enhancing energy production and initiating a cascade of biological responses important for cellular health. PBM’s effects are primarily attributed to its stimulation of cytochrome c oxidase (CcO) within the mitochondrial electron transport chain and activation of heat/light-gated ion channels. These actions facilitate increased ATP synthesis, nitric oxide (NO) release, reduced oxidative stress, and altered gene transcription factors, although the full scope of the mechanisms remains unclear. The therapeutic potential of PBM in AD lies in its multifaceted approach to disease pathology modulation. By influencing mitochondrial function, PBM can directly affect the neurodegenerative processes central to AD. Additionally, its role in modulating inflammatory responses, encouraging cell proliferation, and enhancing cellular signaling pathways positions PBM as a promising therapeutic option for AD (4–6).

Brain PBM devices can be marketed in the U.S. as low-risk general wellness products for mental acuity without FDA clearance, but specific medical claims require official FDA approval (7).

The subsequent sections will elucidate how these mechanisms translate to observable changes in biomarkers and brain function. Changes in brain function are represented by the restoration of disrupted brain waveforms/oscillations and networks in AD, as illustrated in Figure 2.

PBM’s versatility as a single intervention that has not been associated with major side effects underscores its potential as a safe neurological therapy for traumatic brain injury as an example. The capacity for personalization and adaptability to continuous experimentation further enhances its appeal for addressing the complex pathology of AD (8).

The pathophysiological model of AD presented here is intended to be comprehensive in breadth, showing the progression from genesis to symptoms in progressive layers. Figure 3 schematically presents the progression, drawing on existing literature.

AD pathophysiology extends beyond the well-documented Aβ plaques and neurofibrillary tangles (NFTs) to encompass a range of exogenous factors (environmental factors, infections) and endogenous factors (genetic predispositions, blood–brain barrier integrity, cerebral blood flow, vascular health, gut-brain axis and microbiota, glymphatic system, metabolic syndrome, insulin resistance and dyslipidemia).

A significant aspect of AD pathology includes mitochondrial dysfunction, which is implicated in Aβ aggregation, NFT formation, neuroinflammation, oxidative stress, calcium dysregulation, and reduced energy production and metabolism.

The model categorizes the progression of AD into pathogenesis, highlighting the role of both exogenous and endogenous factors; mitochondrial dysfunction as a critical underpinning of disease progression; the precursors to AD symptoms, such as loss of neurons and synaptic connectivity, volume, and neurotrophic growth factors; and the expression of AD symptoms, notably cognitive decline and behavioral changes.

Recent discoveries have shown that AD affects brain networks and waveforms, making these expressions convenient avenues to guide PBM interventions.

In summary, this model delineates the complex interplay among factors contributing to AD and illustrates how diverse PBM mechanisms of action offer promising pathways for intervention. By targeting many of these pathophysiological factors, PBM presents a multifaceted approach to mitigating AD progression.

The various pathophysiological factors in the model, under different progressive layers are expounded in the sections below.

The genesis of AD pathology is influenced by genetic factors, environmental factors, infections, blood–brain barrier integrity, cerebral blood flow, and vascular health.

It can be argued that the genesis or origin of AD pathology is characterized by a complex interplay of genetic and environmental factors, which makes its onset challenging to predict. Key genes implicated in AD include amyloid precursor protein (APP), presenilin 1 (PSEN1), presenilin 2 (PSEN2), and apolipoprotein E (APOE) (9). Notably, the APOE gene’s ε4 allele is a significant risk factor for late-onset AD (10) and is associated with an elevated risk of cerebral amyloid angiopathy and age-related cognitive decline, even during the normal aging process (11). Conversely, the ε2 allele is associated with a reduced risk of AD. This intricate genetic landscape presents considerable hurdles in the development of effective APOE-targeted therapies, with no successful long-term interventions to date (12).

However, mutations in mitochondrial DNA (mtDNA), whether inherited or accumulated over time, can lead to mitochondrial damage, compromising their function and ultimately resulting in cell death and disease (13). Mutations in mtDNA can cause cognitive deficits like those seen in AD, highlighting the importance of mtDNA in proper cognitive function (13). Additionally, increased oxidative damage to mtDNA, due to its proximity to reactive oxygen species (ROS) generation, can give rise to mutations that affect mitochondrial function and their abundance (14). Therefore, mutations in mtDNA can disrupt mitochondrial bioenergetics, leading to energy deficits in neurons and contributing to the pathogenesis of AD.

In addition, defects in genes like the DNM1L and MFF, which mediate mitochondrial fission, have been associated with diseases characterized by abnormal mitochondrial morphology and function (15).

PBM restores mitochondrial health, which is critical for dealing with this genetic modification (16, 17). The effect of PBM on mitochondrial function is further elaborated in the relevant sections to follow.

PBM review studies have touched on the genetics of AD (18–20) but it is apparent that PBM does not directly mitigate the genetic risks associated with the onset of AD or alter the disease’s progression at the genetic level. However, evidence shows that PBM can alleviate AD symptoms and provide temporary cognitive improvements without reversing the underlying genetic factors. For example, oxidative stress can damage nuclear DNA (21), which may be addressed by the PBM’s ability to reduce oxidative stress (22).

Saltmarche et al.’s 2017 study provided valuable insights into PBM’s therapeutic potential, observing notable cognitive enhancements in dementia patients after 12 weeks of treatment (810 nm wavelength pulsing at 10 Hz). However, this was not sustained after treatment, and the patients rapidly resumed progressive decline (23). This pattern was echoed in a study on another progressive neurodegenerative disease, chronic traumatic encephalopathy (CTE), which is related to repetitive traumatic brain injury (TBI), in which patients experienced symptom relief during PBM treatment (810 nm wavelength pulsing at 40 Hz) that receded once the treatment ceased but improved again with resumed therapy (24).

These observations underscore that although PBM may offer symptomatic relief in progressive diseases like dementia, its effects appear to be temporary, necessitating ongoing treatment to sustain improvements. Genetic predispositions, as evidenced by the presence of specific alleles like APOE ε4, seemingly resume their influence on disease pathology once PBM treatment is discontinued. Based on these small studies, the findings highlight PBM’s role in managing downstream pathophysiology symptoms rather than altering the genetic trajectory of AD. They also point to the necessity for regular, possibly long-term, PBM treatment to maintain its physiological benefits.

Environmental factors form part of the complex pathophysiological landscape of AD. Studies have shown that exposure to environmental toxins, such as heavy metals, air pollution, and industrial chemicals, can contribute to the risk of developing AD. Chronic exposure to biotoxins produced by bacteria, molds, and viruses can lead to cognitive decline and the pathophysiology of AD (25). Heavy metals like lead, cadmium, and manganese are known neurotoxicant that have also been linked to AD pathologies (26). Environmental contaminants identified in postmortem tissues of patients with AD include pesticides, flame retardants, plastics, and industrial pollutants (27). Exposure to cigarette smoke, polluted air, and pesticides negatively impacts brain health and increases the risk of AD (28).

Shortly after the Gulf War in 1990–1991, service men and women began reporting multiple symptoms ranging from persistent headaches, widespread pain, chronic fatigue, cognitive dysfunction, mood dysregulation, gastrointestinal issues, skin abnormalities, and respiratory problems. This condition is known as Gulf War Illness (GWI), and it is caused by neurotoxic exposure leading to glutamate excitotoxicity (29). In a blinded, randomized study of 48 patients with GWI, PBM produced increased concentration, relaxation, and sleep (30). Improved GWI outcomes with PBM therapy were also shown in a smaller case series (31). These GWI cases have shown that PBM can reduce the effects of environmental neurotoxins that might have contributed to AD.

Externally caused TBI as an environmental factor has been found to be a potential risk factor for AD or intensifying the risk (32). Over the years, research has shown that the mechanisms of PBM can alleviate the complex pathophysiological aspects of TBI, leading to positive outcomes in clinical studies (8).

There is increasing suggestion of a potential link between infections and AD pathology. Specific pathogens, such as herpes simplex virus (HSV-1) and periodontal pathogens (33), have been implicated in AD development (34).

A meta-analysis to address the relationship between bacterial infection and AD found over a 10-fold increased occurrence of AD when there is detectable evidence of spirochetal infection (35).

During infections, Aβ functions as an antimicrobial peptide in the innate immune defense within the brain. It could play a role in the brain’s defense against pathogens. However, the burden of chronic infections can increase the risk of Aβ misfolding, potentially contributing to AD pathology. This implies that addressing infections is an important factor in AD therapy (36, 37).

There is no clear evidence that PBM can directly treat an infection as a drug. However, there is evidence that PBM can alleviate the symptoms of infection because it can treat the pathophysiology by boosting the immune system. This was the findings of a large-scale controlled clinical trial on the effects of PBM against COVID-19 (38). It is believed that the success of this treatment is attributable to the PBM’s ability to support the immune system to defend against infection, reduce inflammation, and accelerate wound healing.

Blood–brain barrier (BBB) integrity, cerebral blood flow, and vascular health interact with each other and are discussed here.

Recent research on the gut-brain axis has advanced our understanding of AD progression. The microbiota-gut-brain axis, a complex communication network linking the intestinal microbiota with the brain (62), could play an important role in the development and advancement of AD.

The gastrointestinal microbiota is known to affect the synthesis of various neurotransmitters and neural modulation compounds, thereby influencing brain function. Certain gastrointestinal bacteria can produce neurotransmitters such as glutamate, GABA, serotonin, and dopamine. These biochemicals are crucial to brain function and overall cognition (63).

Alterations within the microbiota-gut-brain axis are associated with the initiation and escalation of neuroinflammatory processes. These processes can release pro-inflammatory cytokines, ROS, and other neurotoxic molecules that contribute to neuronal damage (64).

Pathological changes in gut microbiota composition, often marked by increased gut barrier permeability and immune cell activation, are linked to compromised BBB function. This treatment can enhance neuroinflammation, promote neuronal loss, and thereby accelerate AD progression (65).

Studies have identified specific bacterial genera linked to AD pathology, suggesting a direct connection between gut bacterial products and the amyloid cascade in sporadic AD (66). Furthermore, taxonomic alterations in the gut microbiota present in AD offer new avenues for interventions targeting this axis (67).

Innovative treatments, including fecal microbiome transplants, have shown that modifying the gastrointestinal microbiota can improve outcomes (68). This approach opens therapeutic opportunities for PBM in treating AD and other neurodegenerative disorders because of its potential to modify the gut microbiota. Research using gut microbiota-targeted PBM in AD mouse models has yielded promising results (69). Administering PBM at specific red and NIR wavelengths directly to the abdomen improved cognitive function, reduced amyloidosis, and altered intestinal microbiota diversity, suggesting that PBM targeted to the gut may offer a non-invasive approach to modulating microbiota and mitigating AD pathology (69).

Studies on Parkinson’s disease (PD), particularly those delivering PBM to the abdomen, have provided insights relevant to AD. A 2019 review highlighted that PBM altered the microbiome toward a healthier composition in mice (70), and a subsequent human study observed microbiome changes in patients with PD following PBM treatment (71). Applying light on the abdomen directly exposes the microbiome to photonic energy, which could have a more immediate impact on bacterial cellular processes and signaling compared to transcranial irradiation.

In summary, the intricate relationship between the microbiota-gut-brain axis and AD underscores the relevance of this axis in AD development. Disruptions in this axis that lead to neuroinflammatory processes and neuronal damage are potential targets for PBM intervention. By targeting the gut microbiota, PBM has demonstrated promising outcomes in AD models, reinforcing its potential as a therapeutic modality for AD and highlighting the need for further research in this promising field.

The glymphatic system is a crucial macroscopic waste clearance pathway in the central nervous system, leveraging a network of perivascular channels to facilitate the removal of soluble proteins and metabolites (72). Its significance in AD pathogenesis has become increasingly apparent, particularly in its role in clearing Aβ and tau proteins, which are hallmark markers of AD.

Recent research has revealed an association between glymphatic system dysfunction and the accumulation of Aβ, showing that impairments in glymphatic clearance mechanisms contribute to AD development (73). Aquaporin-4 (AQP4) water channels are instrumental in this system, aiding the clearance process. Disruptions in glymphatic function, often due to mislocalization of AQP4, have been linked to AD pathology, making AQP4 a potential target for therapeutic intervention (74).

The activity of the glymphatic system is notably enhanced during sleep, with a significant portion of waste clearance occurring in this state (75). The decline in glymphatic efficiency with age is correlated with sleep disturbances, indicating a potential connection between sleep quality, glymphatic function, and the progression of neurodegenerative disorders like AD. Thus, interventions targeting sleep and glymphatic flow may offer novel approaches for modifying disease trajectory in AD (76).

PBM has emerged as a promising modality for augmenting glymphatic flow and enhancing the clearance of brain waste, including Aβ aggregates. By potentially increasing AQP4 permeability and stimulating cerebrospinal fluid flow, PBM can facilitate the removal of neurotoxic aggregates, thereby reducing AD progression. Moreover, the application of PBM during nocturnal hours may improve sleep quality, further supporting glymphatic function and offering a synergistic approach to managing AD pathology (75, 77).

Recent findings also show that PBM by possibly modulating brain activity at gamma frequencies, could activate peptides that upregulate glymphatic activity, enhancing amyloid clearance (78). Given that transcranial PBM has been shown to affect the AQP4 channel for glymphatic flow and can train gamma waves in the brain at 40 Hz [along with alpha (8–12 Hz) and beta (13–30 Hz)] (79), points to PBM’s potential utility in improving glymphatic function.

In summary, the glymphatic system’s role in removing Aβ and tau proteins underscores its role in AD pathogenesis. Emerging evidence show that PBM enhances glymphatic function and waste clearance, showing a novel therapeutic strategy for AD progression. By potentially improving AQP4 channel permeability and sleep quality, PBM is a promising adjunctive treatment to bolster glymphatic efficiency and mitigate the impact of AD.

Insulin resistance affects the brain’s glucose utilization, leading to energy deficits in neuronal cells, which may increase the risk of neurodegenerative diseases. Metabolic syndrome, characterized by insulin resistance, is significantly associated with a heightened risk of AD (80). This condition, sometimes referred to as “type 3 diabetes,” underscores the critical role of impaired glucose metabolism in AD development. Insulin is not only crucial for metabolic processes but also plays a significant role in learning and memory, showing that its dysregulation could contribute to cognitive decline (81).

Obesity, a key component of metabolic syndrome, induces chronic inflammation through increased ROS production due to lipotoxicity in adipose tissue. The inflammatory state exacerbated by obesity can damage cells and has been identified as a risk factor for AD (82).

Dyslipidemia, which is marked by abnormal blood lipid levels, such as high LDL cholesterol and triglycerides and low HDL cholesterol, is also a component of metabolic syndrome (83). This imbalance can lead to the conversion of systemic cholesterol to 27-hydroxycholesterol, which may cross the BBB, facilitating the deposition of Aβ and tau proteins, hallmarks of AD pathology (84). Dyslipidemia under pathological conditions may disrupt the BBB, alter the processing of amyloid precursor proteins (APP), and contribute to AD development (85).

PBM has been explored for its potential to address metabolic dysfunction. A previous study demonstrated that PBM can reduce blood glucose and insulin resistance and reverse metabolic abnormalities in skeletal muscle in diabetic mouse models (86). Improvements in insulin sensitivity and glucose metabolism, which are pivotal in metabolic syndrome, showing that improving insulin resistance and metabolic abnormalities could offer protective effects against AD.

Further research on obese and hyperglycemic mice treated with PBM showed significant reductions in body mass, blood glucose levels, and inflammatory infiltrates in abdominal adipose tissue after 4 weeks (87). These findings highlight PBM’s potential in mitigating dyslipidemia, further underscoring its potential role in reducing the risk or progression of AD.

In summary, the connection between metabolic syndrome, which is characterized by insulin resistance and dyslipidemia, and the increased risk of AD is becoming increasingly clear. PBM has shown promise in addressing these metabolic dysfunctions, potentially offering a non-invasive strategy to mitigate the risk factors associated with AD. By improving insulin sensitivity and glucose metabolism and reducing inflammation associated with dyslipidemia, PBM could play a role in preventing or slowing AD progression.

In our discussion of genetic factors, we explored how mutations in mtDNA lead to mitochondrial damage and dysfunction. This dysfunction contributes to cellular death and disease, including AD. Mitochondrial dysfunction affects mitochondrial bioenergetics, resulting in energy shortages within neurons, leading to AD pathogenesis. The critical involvement of mitochondria in AD pathology has led many researchers to consider the mitochondria-cascade hypothesis (MCH) as a key target for addressing the disease. MCH posits that deteriorating mitochondrial function triggers a series of downstream cellular changes characteristic of late-onset AD, encompassing Aβ amyloidosis, tau phosphorylation, oxidative stress, synaptic loss, and neurodegeneration (88).

Further discussion of pathophysiological factors such as Aβ plaques, neurofibrillary tangles (NFT), neuroinflammation, oxidative stress, energy deficit, and growth factor dysregulation highlights their connections to mitochondrial dysfunction. These reviews underscore the interconnectedness of these aspects with mitochondrial health, emphasizing the fundamental role of mitochondria in the broader landscape of AD pathology.

The formation of Aβ plaques is a hallmark of AD pathology and is characterized by the abnormal accumulation of Aβ peptides in the brain (89). These peptides, derived from the cleavage of amyloid precursor protein (APP), are closely associated with the genetics and pathogenesis of AD (90). The enzymatic actions of beta and gamma secretases on APP produce Aβ fragments, which then aggregate into insoluble plaques, disrupting cellular function and contributing to neuronal damage and death (91, 92).

A pivotal controlled study in 2011 on presymptomatic transgenic mice presenting an Aβ protein precursor demonstrated that PBM significantly reduced the count of Aβ plaques, as observed in plasma samples. PBM treatment reduced the behavioral symptoms associated with advanced amyloid deposition and decreased the expression of inflammatory markers. Furthermore, it resulted in enhanced ATP levels, improved mitochondrial function, and increased c-fos expression, indicating an overall enhancement of neurological function (93).

Subsequent research further validated PBM’s efficacy in reducing Aβ deposition in the cerebellar cortex and NFT in the cerebral cortex and cerebellum of transgenic mice after a month of treatment (94).

PBM has been shown to influence the activity of microglia, among the brain’s primary immune cells, by downregulating Ca²⁺ and promoting microglial polarization toward an M2 phenotype. This polarization enhances the phagocytosis of Aβ plaques and modulates the expression of anti-inflammatory and inflammatory factors (95). The M2 microglia phenotype decreases an enzyme associated with the production of ROS, thereby reducing neuronal death (96). A previous study remarkably revealed that light flickering at 40 Hz could activate microglia to significantly reduce the Aβ burden in the visual cortex (97). Adding sound resonating at 40 Hz reduces Aβ burden in the auditory cortex and other parts of the brain (98).

However, a subsequent replicating study challenged these findings (99). Another study found that 10 Hz of PBM was more effective than 40 Hz in activating M2 microglia and clearing Aβ plaques (100). This suggests a reconsideration of whether 40 Hz is best for performing these functions or whether a combination of these or other frequencies would be better. This is further critically analyzed in a later section on Aberrated Brain Waveforms Expression, Gamma, and on proposed PBM parameter settings in Considerations for PBM parameters to Maximize Potential Outcomes for Alzheimer’s, Pulse rate of 40 Hz, 10 Hz and 0 Hz (continuous).

Studies propose that PBM could directly or indirectly affect the aggregation state of Aβ. Direct irradiation with red light that been observed to reduce Aβ aggregation (101). It has been suggested that a photoelectric coupling effect alters protein structures, diminishing Aβ aggregation and toxicity, and that NIR light is capable of disassembling Aβ in vivo (102).

Moreover, PBM may facilitate the reduction of Aβ deposits by enhancing clearance mechanisms, notably through the activation of the glymphatic system (77)—a component of AD pathogenesis discussed in the Glymphatic System section.

The dysfunctional BBB, which impedes the clearance of Aβ from the brain, is directly implicated in AD development (103). The role of the BBB in AD pathology and PBM’s potential to support BBB functions are elaborated in the section on Blood–Brain Barrier Integrity, Cerebral Blood Flow, and Vascular Health.

Despite regulatory directions, there are ongoing debates and controversies surrounding the efficacy of targeting Aβ in AD treatment, which underscore the usefulness of exploring beyond Aβ and tau aggregation for therapeutic strategies. PBM stands out as a promising single intervention capable of addressing the complex pathophysiology of AD through its multifaceted actions. The potential benefits of PBM as a comprehensive approach to AD treatment in these debates will be discussed in a later section, PBM as a Multifaceted Approach to AD Pathophysiology Amidst Debates.

NFTs within neurons are another defining feature of AD pathology (104). These tangles are composed of the protein tau, which, in the context of AD, undergoes abnormal phosphorylation. This process causes tau to aggregate into tangles, disrupting the internal transport system of neurons and contributing to neuronal death (105). Given their role in AD pathology, tau-targeting therapies are considered promising for treating AD and related tauopathies (106, 107).

Research highlights the potential of PBM in addressing tau pathology. An animal study published in 2014 explored a model that developed NFTs and found that after four weeks of PBM treatment, there was a significant reduction in hyperphosphorylated tau, NFTs, and oxidative stress markers in the neocortex and hippocampus, approaching levels observed in wild-type (control) animals (108).

In support of this research, a 2022 study utilized AD-like transgenic rat models with marked increases in paired helical filament (PHF) intensity—an abnormal tau protein structure within NFTs—in both the cortex and hippocampus of AD rats compared with wild-type rats. PBM treatment significantly reduced elevated PHF intensity in AD rats, with no notable differences observed in wild-type rats treated with or without PBM (59).

Microtubules (MTs), which are essential for maintaining neuronal structure and function, are polymerized from tubulins. In AD, hyperphosphorylated tau loses its ability to bind to and stabilize MTs. PBM at an NIR wavelength of 810 nm pulsing at 10 Hz, to facilitate temporary transitions in tubulin structures, potentially enabling autophagy and the renewal of MTs (109).

In summary, the evidence underscores the potential of PBM in mitigating one of the key pathological markers of AD—NFTs. This reduction in NFTs appears to be closely linked to PBM’s capacity to diminish abnormal tau protein phosphorylation. Additionally, PBM’s influence on the structural dynamics of microtubules, which are crucial for neuronal integrity, further illustrates its therapeutic promise in the context of AD.

Neuroinflammation is a pivotal element in AD pathology, with the brain’s resident immune cells, microglia, playing a crucial role in this inflammatory process. These cells are activated by the presence of Aβ plaques and NFTs, and initially serve a protective role by attempting to resolve these pathologies. However, the transition from acute to chronic inflammation, sustained by ongoing activation of microglia and other immune cells, contributes significantly to neuronal damage and accelerates AD progression (110). This continuous immune response not only aggravates the accumulation of Aβ and tau protein but also propels the disease’s pathological processes further (111).

Recent research has broadened the perspective on inflammation’s role in AD, underscoring the importance of both localized neuroinflammation and systemic inflammation. Intriguingly, studies have linked systemic and intestinal inflammatory responses, integral to the gut-brain axis, with AD progression, suggesting a comprehensive inflammatory backdrop that spans beyond the central nervous system. These systemic inflammatory conditions have been implicated in intensifying neuroinflammation, promoting tau hyperphosphorylation, impairing Aβ clearance, and weakening the integrity of the BBB, all hallmarks of AD pathology (112).

PBM has been identified as a potential therapeutic approach for modulating intricate inflammatory processes in AD, addressing both brain-specific and systemic inflammation. In a notable study, daily whole-body PBM treatment using a 40-Hz gamma frequency flicker demonstrated anti-inflammatory effects in the brain and systemically in mice 10 days before an inflammatory challenge. This treatment regimen effectively downregulated proinflammatory cytokines linked to inflammasome activation, such as IL-1β and IL-18, and enhanced the levels of the anti-inflammatory cytokine IL-10 (113).

Further evidence supporting PBM’s anti-inflammatory capabilities comes from a systematic review of controlled animal studies, which confirmed PBM’s potential in mitigating neuroinflammation (114). Additionally, a literature review of PBM therapy’s efficacy in treating pain and inflammation highlighted its beneficial impact on proinflammatory biomarkers. These findings collectively highlight PBM’s capacity to attenuate inflammatory responses (115), showing its viability as a non-invasive treatment option for countering inflammation-associated pathological processes in AD.

In summary, the critical role of inflammation, both within the central nervous system and systemically, in driving the progression of AD from amyloid and tau pathology to cognitive decline has been increasingly recognized. Targeting these complex inflammatory pathways, PBM is a promising therapeutic strategy, offering potential benefits in reducing inflammation and thereby slowing AD neuropathological progression.

Oxidative stress, a factor in AD development, arises from an imbalance between reactive ROS production and the body’s ability to neutralize its damaging effects. This imbalance is further exacerbated by mitochondrial dysfunction, which not only leads to diminished energy production but also escalates further oxidative stress, creating a self-reinforcing cycle of cellular damage (116). The cellular damage from mitochondrial dysfunction and oxidative stress is a driver in AD’s progression (117, 118). The process includes increased ROS production, oxidative damage to cellular lipids, proteins, and DNA, and reduced ATP generation efficiency. This scenario also underscores reduced energy metabolism, which is hampered by decreased activity of enzymes involved in oxidative phosphorylation (118).

Although mitochondrial dysfunction is a primary source of oxidative stress in AD, additional external factors, such as environmental pollutants, diet, metal exposure, and infections, also contribute to the oxidative burden (118, 119).

Although the metabolic activities of PBM and ATP production activate ROS in a transient manner, they alleviate oxidative stress by increasing mitochondrial membrane potential, restoring calcium homeostasis, activating synaptic signaling pathways, upregulating antioxidant enzymes, and improving overall mitochondrial function (17, 120, 121). Specific studies using hippocampal cell lines from sacrificed mice demonstrated that PBM enhances the activity of antioxidant enzymes in the hippocampus, effectively reducing ROS levels and oxidative stress there (122).

In summary, the reciprocal relationship between oxidative stress and mitochondrial dysfunction plays a significant role in AD pathogenesis, contributing to a cycle of chronic neuronal damage. Although PBM activates low-level transient ROS, it intervenes in this cycle by improving mitochondrial function, signaling pathways, restoring calcium homeostasis, and stimulating the brain’s antioxidant defenses. By directly diminishing oxidative stress, PBM is a potential therapeutic strategy for combating AD pathology.

Calcium is a crucial cellular messenger that plays essential roles in synaptic transmission, neuronal excitability, and signal transduction. Mitochondrial dysfunction intensifies calcium mishandling, leading to calcium dysregulation in homeostasis. Disruption in normal calcium homeostasis can induce formation of Aβ plaques, accumulation of NFT, and dysfunction of synaptic plasticity, which, in turn, can affect calcium homeostasis, thereby forming a vicious cycle (123, 124).

Calcium ion (Ca²⁺) homeostasis and related mechanisms are responsible for learning and memory. In AD pathology, Aβ can disrupt Ca²⁺ signaling through several mechanisms with increased influx of Ca²⁺ from the extracellular space and dysregulating its release from intracellular stores (125). Intracellular calcium dysregulation may contribute to synaptic dysfunction, neurodegeneration, and cognitive impairment observed in AD (126).

A study found that 650 and 808 nm (not 1,064 nm) light promotes intracellular Ca²⁺ elevation. Ca²⁺ release from endoplasmic reticulum is activated by ROS generated by PBM (127), which hypothetically balances extracellular influx in AD. Balanced calcium influx supports neuronal activity and contributes to physiological processes essential for learning and memory (128). As an additional note, NIR light can influence calcium channels, leading to an increase in cytosolic calcium levels while decreasing mitochondrial calcium concentrations (127). The total effect of calcium dynamics on neuronal function and cellular homeostasis can be significant in the context of AD.

In summary, PBM’s capacity to adjust calcium dynamics reflects its therapeutic potential in restoring neuronal and cellular homeostasis affected by AD. This indicates that PBM can be a non-invasive strategy to mitigate calcium-related disruptions in synaptic function and neurodegeneration, providing a promising avenue for AD treatment and cognitive impairment mitigation.

Altered energy production and metabolism impact the development and progression of AD. Metabolic alterations in the aging brain and AD-related metabolic deficits are associated with glucose metabolism dysregulation, glycolysis dysfunction, the tricarboxylic acid (TCA) cycle, oxidative phosphorylation (OXPHOS) deficits, and pentose phosphate pathway impairment (129). These factors are intricately related to mitochondrial function (130).

Mitochondria play a crucial role in the production of adenosine triphosphate (ATP), the cell’s energy currency, which is essential for maintaining cellular functions, particularly in high-energy-demanding cells like neurons. Therefore, problems with mitochondria could be major contributors to AD pathology (131).

A decline in glucose availability in the brain compromises cellular respiration. This condition leads to metabolic stress that alters the processing of Aβ protein precursors associated with Aβ plaques and tau tangles, which are characteristic pathological features of the disease (130).

Patients with AD exhibit reduced levels of nicotinamide adenine dinucleotide (NAD) and altered mitochondrial metabolism. These inherent deficiencies in energy management may contribute to neural dysfunction and cellular degeneration, potentially leading to AD (132).

A systematic review showed that PBM can restore mitochondrial function (133). This is further elaborated in a previous section, Mitochondrial Dysfunction.

In summary, PBM can effectively restore mitochondrial function, enhance ATP production, and improve cellular energy management. By targeting the underlying mitochondrial and metabolic dysfunctions in AD, PBM is a promising therapeutic approach that can potentially slow the progression of AD.

In AD, changes in brain networks play a role in the progression of the condition.

The brain network tends to shift toward a more random structure as AD progresses. Alterations in network characteristics, particularly at the earliest stage of the disease, lead to changes in functional connectivity involving the somatomotor, frontoparietal, and default mode modules (145).

AD-related changes in brain networks are also widespread and extend beyond affecting memory and attention, affecting sensory and motor circuits. These changes challenge previous assumptions about AD’s effects and show that early-stage AD may exhibit broader cognitive impairment that is detectable during mild cognitive impairment (MCI) (146). These findings propose that the effect of AD is more global.

Different spatial brain networks are linked to different clinical phenotypes of AD, highlighting the diverse impact of AD on brain network modulation. The presence of misfolded protein aggregates characterizes neurodegenerative disorders like AD, leading to alterations in large-scale functional brain network organization, including language, dorsal attention, frontotemporal, and default mode networks (147).

The most widely studied resting state network is the default mode network (DMN), which has been associated with mind wandering, autobiographic memory, future thinking, and introspection (148). Its activity can reasonably be considered abnormal in AD and distinguishes AD from healthy aging (149).

Aβ accumulation disrupts DMN connectivity, even in cognitively healthy individuals, indicating an early involvement of the DMN in the disease process. Higher amyloid burden is associated with aberrant DMN connectivity and predicts longitudinal memory decline, pointing to a crucial link between amyloid deposition, DMN dysfunction, and cognitive decline (150).

PBM has shown promising effects on brain networks in the context of AD pathology in several ways by addressing the causes of network aberrance. It enhances neuronal activity, rebuilds damaged neuronal networks, and stimulating the production of neurons (151). It can effectively reduce amyloid plaque burden, improve mitochondrial function, increase ATP levels, and enhance cognitive function in animal models of AD. Moreover, it has demonstrated cognitive improvement, enhanced sleep quality, reduced behavioral symptoms, and increased brain perfusion in patients with mild to moderately severe dementia (19). It enhances synaptic connections, reduces synaptic degeneration, neuronal apoptosis, and neuroinflammation, and improves cognitive function in in vitro and in vivo models. Studies suggest that PBM modulates gene regulatory networks related to synaptic connections, with behavioral alterations, such as improved memory and reduced seizure scores, observed in PBM-treated mice (144). These effects lead to better brain networks.

Therefore, PBM is a promising tool to target the DMN in AD. Targeting DMN nodes, Saltmarche et al. studied 5 dementia patients with a PBM device that targeted the delivery of NIR light pulsed at an alpha frequency of 10 Hz to these nodes. They observed significant improvements over 12 weeks of treatment (23). In a later controlled study, Chao similarly targeted the DMN with PBM but delivered it at 40-Hz gamma frequency, on 8 patients (4 in active treatment, and 4 in usual care) over 12 weeks. Significant cognitive improvements were also observed (152), and fMRI revealed increased cerebral perfusion and increased connectivity between the posterior cingulate cortex and lateral parietal nodes within the DMN in the PBM group. This is elaborated further in the section, Optimizing PBM Parameters for AD Treatment, Optimizing LED Brain Network Positioning, to follow.

In summary, Brain network alterations are characteristics of AD. PBM addresses these brain network alterations by enhancing neuronal activity, reducing amyloid plaque burden, improving mitochondrial function, and increasing ATP levels, which collectively contribute to rebuilding damaged neuronal networks and stimulating neuronal production. These underlying mechanisms manifest as improved cognitive functions, enhanced sleep quality, and reduced behavioral symptoms, all supported by increased brain perfusion in patients with AD. They contribute to overall brain network health. PBM therapy, when targeted at the DMN nodes, brings these benefits to a network implicated in AD, achieving significant cognitive improvements in patients with AD. These findings underscore PBM’s potential as a non-invasive therapeutic strategy for addressing the complex changes in the DMN and other brain networks associated with AD.

Connecting brainwaves or oscillations to AD is an emerging research area in AD pathology. Brainwaves are electrical patterns produced by the brain that can be measured by EEG. These brainwaves reflect the communication between neurons in the brain and are categorized by frequency and amplitude. There are five major types of brainwaves: 1. Delta Brainwaves: 0.5–4 Hz, 2. Theta Brainwaves: 4–8 Hz, 3. Alpha Brainwaves: 8–12 Hz, Beta Brainwaves: 12–30 Hz, Gamma Brainwaves: 30–100 Hz. These frequencies represent the speed at which brainwave patterns oscillate and are measured in cycles per second or Hertz (Hz). Each type of brainwave is associated with different mental states and activities, ranging from deep sleep and relaxation to heightened perception and problem-solving tasks. Brainwaves provide important insights into AD for early detection and therapeutic intervention.

The gamma frequency of 40 Hz has recently attracted significant attention. A pivotal 2016 study by researchers at the Massachusetts Institute of Technology (MIT) revealed that exposing AD mouse models to flickering light at this specific gamma frequency led to notable improvements in AD symptoms and markers. The findings revealed enhanced behavioral outcomes, activation of microglia and a substantial reduction in amyloid plaque accumulation within just 7 days, a remarkable finding at the time (97). Since then, the group has conducted a 3-month clinical trial on humans stimulated with light and sound at 40 Hz, but no significant change in cognition. However, there were improvements in ventricular size, stabilization of hippocampal size, and functional connectivity in both the DMN and medial visual network, as well as circadian rhythmicity after 3 months of stimulation (153). This area of research has settled into investigating audiovisual sensory stimulation (154) but not without detractors (99). In another smaller trial with only 40-Hz light flickering, there was no report of significant cognitive changes, but increased gamma neural activity was observed during stimulation (155). A similar device was later evaluated in a randomized controlled study involving 76 patients with mild to moderate Alzheimer’s Disease (AD), using an active-to-sham ratio of 2:1. The study successfully met its primary safety endpoint and demonstrated a 76-77% slower cognitive decline from baseline in the active treatment group compared to the sham group that was nominally significant (156). There is now a new clinical trial to follow this (157).

Gamma oscillations, which play a role in cognitive functions like memory, are disrupted in early AD, even before Aβ overproduction (158).

Murty et al. visually induced gamma oscillation in a large elderly population with mild cognitive impairment (MCI). The results demonstrated weaker gamma oscillations in individuals later diagnosed with early AD, particularly in the brain region responsible for processing visual images (159).

Based on these findings, restoring gamma oscillations is being explored as a potential therapeutic approach for AD, with the aim of improving cognitive function and intra-brain communication (160). However, some studies reported elevated gamma activity already present in patients with AD (161, 162), which cautions us not to be dogmatic about the need to increase gamma levels in AD brains. Gaubert et al. postulated that gamma power falls as the increase in amyloid burden level crosses a certain threshold level in later stages of AD. However, gamma power is high in preclinical AD, reflecting compensatory mechanisms (163). Based on the evidence, the gamma intervention should primarily be for achieving physiological outcomes, and whether it is present in patients with AD should be of little consequence. The patterns take care of themselves when their physiology improves.

A recent study revealed that shining light flickering gamma at 40 Hz activate the VIP peptide to drive the glymphatic system for better amyloid clearance, which contributes to improving AD physiology (78). This offers the glymphatic systm as an intervention target at 40 Hz.

In the preceding sections, we explored a range of pathological factors contributing to neuronal death, as well as the potential therapeutic applications of targeting these factors using PBM. These interventions to prevent neuronal death can be deemed neuroprotective. In the following discussion, our attention will shift to neural regeneration or neurogenesis.

Evidence indicating a deceleration in the progression of dementia and potential signs of recovery indicates that PBM stimulates neurogenesis. The mechanisms underlying this phenomenon are proposed below.

Research indicates that PBM can stimulate the growth of neural stem and progenitor cells into neurons, enhance mitochondrial function to improve the neuronal environment, and reduce inflammation and gliosis, thus contributing to nerve regeneration. Specifically, PBM has been found to activate genetic and signaling pathways that support neuronal differentiation, facilitating the development of progenitor cells into functional neurons (151).

One area of focus has been the hippocampus, where PBM has been shown to improve the survival of new neurons by mitigating inflammasome and activating the AKT/GSK-3β/β-catenin pathway (182, 183). Studies have demonstrated that PBM enhances cognitive function and supports neural progenitor cell activities in models of brain injury and disease, including ischemic stroke and traumatic brain injury. For instance, transcranial PBM treatment for seven consecutive days after photothrombosis induction in a rat model reduced the infarcted area and increased the expression of neurogenesis and synaptic markers (184).

Chronic PBM has been shown to promote adult hippocampal neurogenesis by activating latent transforming growth factor β1 (TGFβ1) in an AD mouse model (185) and enhances the migration and differentiation of neural stem cells in the subventricular zone, a brain region prominently involved in neurogenesis (186).

In summary, PBM stimulates neurogenesis, which is a promising avenue for brain repair. While clinical evidence is encouraging, the studies are still in the early stages of statistical validation. For instance, the study by Chao et al., which was based on a single case of TBI, demonstrated neurogenesis through MRI findings, highlighting the potential of PBM in this area (187).

Synaptic dysfunction is increasingly recognized as a pivotal factor in the pathogenesis of AD, alongside the formation of neuritic Aβ plaques and NFTs of hyperphosphorylated Tau protein (188). Notably, synaptic loss is considered the most significant predictor of cognitive decline in AD (189). The previous sections of this manuscript have explored various pathophysiological mechanisms contributing to AD that are indirectly and beneficially influenced by PBM. In this section, we delve deeper into the role of PBM in promoting synaptogenesis and protecting against synapse degeneration, highlighting its potential therapeutic implications for enhancing synaptic function in AD.

PBM shows significant potential in facilitating synaptogenesis, which is the process of forming synapses between neurons. It aids in the development of dendritic spines, encourages axonal growth, and establishes functional connections between new and existing neurons, contributing to the neural network’s structural and functional integrity (190). In temporal lobe epilepsy models, PBM has been observed to mitigate neurodegeneration and cognitive decline by upregulating synaptic-related proteins, such as neuroligin-3, indicating its role in enhancing synaptic connectivity and cognitive function (144).

Furthermore, PBM has been implicated in promoting functional recovery post-stroke by inhibiting neurotoxic markers, boosting synaptic expression, and modulating apoptotic pathways, thereby highlighting its neuroprotective capabilities (191). Additionally, its application in animal models of anxiety, depression, and AD has demonstrated alleviation of symptoms and neuronal cell death, further underscoring its therapeutic potential in neurodegenerative as well as psychiatric disorders by enhancing nerve fiber and synapse markers (192).

In addition to synaptogenesis and neurogenesis discussed above, PBM contributes to neural network formation by improving excitatory neurotransmission and oxidative metabolism, which are crucial for neuronal survival and differentiation. Long-term transcranial NIR irradiation has been shown to rejuvenate brain metabolism in aging rats to levels observed in younger rats, indicating its role in enhancing neural connectivity and overall brain health (193).

In summary, PBM has the capacity to support synaptogenesis in addition to neural network formation, indicating its further potential as a viable treatment option for AD.

This section provides a collective summary of the preceding findings and analyses, with a critical evaluation of the limitations. PBM offers a promising multifaceted approach to mitigating AD by targeting various pathophysiological factors. PBM has shown efficacy in addressing genetic predispositions, environmental factors, infections, BBB integrity, CBF, vascular health, the gut-brain axis, glymphatic system function, metabolic syndrome, mitochondrial dysfunction, and neuroinflammation.

By improving mitochondrial function, PBM enhances neuronal activity, reduces amyloid plaque and hyperphosphorylated tau burden, and increases ATP levels, contributing to cognitive improvements and synaptic plasticity. Additionally, it stimulates neurogenesis and synaptogenesis, potentially reversing neuronal loss and brain atrophy.

However, it is noteworthy that some findings are inferred rather than directly established. For instance, PBM’s modulation of microglial responses from pro-inflammatory M1 to anti-inflammatory M2 phenotypes suggests a potential for amyloid plaque clearance and reduced neuroinflammation, but this connection is inferred from changes in microglial activity rather than direct evidence of plaque reduction. Similarly, while PBM has been observed to decrease Aβ aggregates in cell models, its direct impact on amyloid pathology in human AD patients remains to be conclusively demonstrated. Furthermore, enhancements in mitochondrial metabolism and improvements in BBB integrity and vascular health through increased CBF are promising, but these effects need further validation in large-scale clinical trials. Current research is limited by small sample sizes, variability in study designs, and a lack of large-scale clinical trials to confirm efficacy and establish standardized treatment protocols, as will be presented in the following section, Systemic review of the clinical evidence on PBM parameters in AD. PBM’s long-term effects and optimal parameters remain under investigation.

While some causal links between certain pathophysiological aspects are still subject to more investigation, it is appropriate to emphasize evidence from human clinical studies, particularly controlled trials. The following sections of the manuscript will review and analyze this clinical evidence and propose potential treatment protocols based on brain networks and waveforms.

This manuscript examined the effects of PBM therapy on AD’s multifaceted pathophysiological aspects, focusing predominantly on cell culture and animal studies. To assess PBM’s efficacy in humans, we conducted a systematic review for identifying the impact of parameters on clinical outcomes. This review focuses on available full-authored human clinical studies on PBM for AD published in peer-reviewed journals up to January 2014. The search was performed using the PubMed, Google Scholar, and Cochrane Library databases with keywords “photobiomodulation,” “Alzheimer’s Disease,” “dementia,” and “clinical studies.” This process identified 7 studies with varying quality and methodologies. We conducted a qualitative analysis of these studies to derive insightful data that may be used to improve the PBM treatment parameters. This systematic review was conducted following the PRISMA guidelines. The findings, along with the qualitative assessment of the included studies, are presented in a summarized table format for clear comparison and analysis. The findings are presented in Table 1.

Historically, the use of low-level lasers of 808 nm and 1,064 nm wavelengths in transcranial PBM has been influenced by their demonstrated efficacy in enhancing neuronal viability and mitigating neurotoxicity, including in the context of AD and other neurological conditions such as strokes (4, 204). These wavelengths have been widely adopted because of their ability to modulate cerebral functions and reduce Aβ toxicity and have been proposed for their synergistic use (95).

More recent studies have shown that wavelengths in the 810 nm and 1,060–1,080 nm range with non-laser LEDs are effective for cognitive improvement and treating neurocognitive impairments, with benefits such as enhanced cerebral oxygenation and improved cognitive and behavioral functioning in conditions like dementia (102). In their review of related evidence, Heiskanen and Hamblin concluded that “the current total evidence appears to support the idea that PBM is not dependent on lasers or coherence” (205). The collective discussions present non-laser LEDs with these wavelengths as viable alternatives to 808 nm and 1,064 nm lasers. The discussion in this section will focus on the wavelengths agnostic of whether they are from laser or LED sources.

There is a debate over the level of tissue penetration and mitochondrial activation offered by each wavelength, with computer modeling providing support for both 1,064 nm in laser irradiation and 1,070 nm in LED (206) irradiation and 808 nm in laser irradiation or 810 nm in LED (207–209). These models differ in terms of their input variables and algorithms, which affect their respective penetration calculations.

Specifically, for intranasal delivery, computer modeling showed that 810 nm offered higher light deposition into the brain than 1,064 nm (210). Empirical studies on human forearms have shown that 1,064-nm lasers maintain increases in oxygenated hemoglobin and longer oxidized cytochrome c oxidase (CcO) (211). Moreover, previous research indicated that 810 nm elicits a higher level of mitochondrial activation than 1,050 nm, with both wavelengths enhancing mitochondrial activity (212).

Salehpour et al. proposed that light between 600 and 850 nm primarily targets the mitochondrial electron transport chain (ETC), boosting neuronal respiratory capacity, as exemplified by the significant enhancement of ATP production at 808 nm (213). Conversely, wavelengths from 1,000–1,350 nm (labeled as NIR II) (214) are thought to be absorbed by structured water clusters in heat/light-gated ion channels, like TRPV1 (215), increasing the vibrational energy that perturbs protein structures and modulates intracellular Ca²⁺ levels (4). This action augmented ETC activity, as evidenced by increased oxidation of CcO upon exposure to 1,064 nm light (216).

It is notable that wavelengths of 750 nm and 950 nm have been found to inhibit CcO activity, advising against their use in PBM for effective AD treatment (217, 218).

In conclusion, although both 808/810 and 1064/1060–1,080 nm groups of wavelengths show potential for scalp application in PBM, computational models indicate a preference for 810 nm for intranasal delivery. Based on these findings, particularly the merits of these two wavelength groups, combining them in an intervention could enhance outcomes. The author is actively engaged in co-investigations employing EEG and fMRI to study brain responses to these wavelengths, and forthcoming research is expected to provide further insights.

The application of PBM for AD faces considerable challenges, not least of which is the shortfall in comprehensive controlled human trials essential for affirming PBM’s therapeutic efficacy. A primary impediment is the impracticality of rigorously testing each newly discovered set of PBM parameters for optimization—ranging from wavelengths to pulse frequencies—through large-scale randomized clinical trials. The logistical and financial constraints of extensive testing limit the evidence base to smaller studies and anecdotal experiences.

Compounding this challenge is the lack of standardized methodologies across studies, leading to inconsistent clinical outcomes and complicating efforts to aggregate data or define universally effective treatment protocols for AD.

An often overlooked but important factor in PBM is the effect of the distance between the LED and the target surface area. The power density emitted by the LED decreases exponentially with distance before reaching the target surface. Many PBM clinical studies report the LED’s output power density but not the actual surface irradiation. This omission raises questions about whether the observed efficacy is due to a placebo effect, especially in studies lacking control groups or objective measures. The notion that personalized PBM treatment protocols could enhance therapeutic outcomes is compelling but remains largely hypothetical. A relatively limited selection of peer-reviewed research and that findings are mostly early-stage findings support the hypothetical status of the protocols. In time, controlled clinical trials will confirm or reject the efficacy of the protocols. However, due to the rapid self-learning nature of AI, it could be a tool that could help to overcome this limitation. For now, there is a significant gap in fully understanding PBM’s potential in treating AD, and the course suggested in this manuscript are just promising early steps.

The understanding of AD pathophysiology, as discussed in this study, draws extensively from existing literature. However, this representation is far from exhaustive, and ongoing debates within the scientific community continue to shape our knowledge. Although current regulatory approaches tend to align with the Amyloid Cascade Hypothesis, with a focus on Aβ as a primary target, this stance is not without controversies. For instance, the initial identification of the Aβ molecule, specifically Aβ-56, as reported in Lesné et al.’s 2006 Nature publication (238), has been scrutinized for alleged image alterations (239). Despite these controversies, the clinical findings that support an increase in cerebrospinal fluid (CSF) Aβ1-42, and in plasma Aβ42/40 ratios, alongside decreases in CSF P-Tau, CSF T-Tau, and plasma p-tau181, have been interpreted by regulators and many researchers as indicative of the reduction of Aβ accumulation. This led to the regulatory approval of lecanemab and donanemab for market release (240, 241), albeit with consideration of potential side effects in ARIA (2).

Some researchers offer alternative perspectives on AD pathology; for instance, Weaver et al. introduced a novel concept that views AD as an autoimmune condition (AD2). This model proposes that Aβ functions as an early responder cytokine with antimicrobial traits, unintentionally targeting neurons because of their similar electrophysiological properties to bacteria. This phenomenon initiates a continuous cycle of neurodegeneration influenced by amino acid metabolism, thereby questioning the conventional Amyloid Cascade Hypothesis (242). In this context, PBM is an effective treatment for autoimmune disorders, an example being Hashimoto’s thyroiditis (243).

Upon reviewing the broader landscape of AD pathophysiology, it becomes evident that the complexity of the disease encompasses far more than the aspects highlighted by the Amyloid Cascade Hypothesis. Many researchers have argued for the critical importance of other pathophysiological elements, advocating for a treatment approach that addresses the different factors or facets of AD pathophysiology highlighted in the various sections of this manuscript. In this context, PBM is a promising, unique intervention capable of addressing various pathophysiological aspects. The potential lies in its ability to modify several underlying mechanisms of AD simultaneously, and importantly, with an established safety record (244).

However, the exploration of PBM as a therapeutic option for AD remains limited, largely due to insufficient engagement from the research community. This lack of investigation into PBM’s full potential of PBMs is attributed to funding challenges rooted in the difficulty of patenting natural light, which diminishes the incentive for significant private research investment. Despite these hurdles, the versatility of PBM as a non-invasive, multifaceted intervention underscores its potential significance in the evolving landscape of AD treatment strategies, warranting further exploration and validation within the scientific and medical communities.

As the exploration of PBM as a potential treatment for AD continues to progress, our understanding of its mechanisms and outcomes is expanding. The continual evolution of research findings necessitates adaptive adjustments to identify the most effective PBM parameters. The challenge of validating each modification through large-scale clinical trials—potentially delaying the application of significant technological advancement—highlights the importance of credible, expedited research strategies. Interdisciplinary collaboration and innovative methodologies stand out as pivotal approaches to refine and validate PBM’s therapeutic application in AD, emphasizing personalized treatments that consider the distinct physiological profiles of patients.

Interdisciplinary research focuses on brain functions, neural networks, and the molecular and protein structures affected by PBM. A key area of investigation is how PBM’s variable pulse frequencies of PBMs influence the polymerization and depolymerization of tubulin into microtubules (245). Such mechanisms may critically impact the formation of NFTs, which are important for AD pathology. Additionally, examining PBM’s effects on cellular electrical field, biophotonic emission, and other mechanotransduction mechanisms offers insights into its potential to enhance cellular communication and health (236).

Incorporating artificial intelligence (AI) into PBM research can significantly accelerate the discovery and validation processes. AI’s ability to model and predict the effects of various PBM parameters can hasten breakthroughs. Moreover, encouraging inter-organizational collaboration can broaden the research ecosystem, facilitating a comprehensive examination of PBM capabilities.

In summary, advancing PBM efficacy in AD treatment requires a concerted effort that combines innovative discoveries, strategic AI utilization, and controlled trials for validation. This comprehensive strategy could pave the way for the establishment of PBM as a viable AD treatment option.